Sodium Butyrate Ameliorates Hepatic Steatosis and Insulin Resistance in MASLD Models With Concurrent Alterations in AMPK and PI3K/AKT Signaling
Frontiers in Bioscience-Landmark · 14.10.2026 · 31 (10)
DOI: 10.31083/fbl55577 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, online erschienen am 14.10.2026. Verfasst von Yinan Zhao und 5 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Medical College of Qinghai University, 810000 Xining, Qinghai, China. Hauptthemen laut MEDLINE: Insulin Resistance, Proto-Oncogene Proteins c-akt, AMP-Activated Protein Kinases, Phosphatidylinositol 3-Kinases. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by dysregulated glucose and lipid metabolism and is closely linked to insulin resistance (IR). Sodium butyrate (NaB) is a short-chain fatty acid with reported metabolic benefits, but its effects on MASLD-related IR remain unclear. This study investigated the therapeutic efficacy of NaB in both palmitate (PA)-induced insulin-resistant hepatocytes and high-fat diet (HFD)-induced MASLD in mice and to elucidate the underlying mechanisms responsible for its effects.
Methods
We evaluated the effects of NaB in PA-treated HepG2 cells and in C57BL/6 mice fed an HFD for 16 weeks followed by 8 weeks of oral NaB administration. Lipid accumulation, glucose metabolism, glycogen storage, transcriptomic changes, and adenosine monophosphate-activated protein kinase (AMPK) and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT) signaling were assessed using biochemical assays, staining, reverse transcription-quantitative polymerase chain reaction (RT-qPCR), western blotting, RNA sequencing, and detection of inflammatory activity.
Results
In PA-treated HepG2 cells, NaB reduced lipid accumulation, improved glucose uptake and glycogen storage, and reduced the secretion of the pro-inflammatory mediators tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-1β (IL-1β), and monocyte chemoattractant protein-1 (MCP-1) in a dose-dependent manner. These effects were accompanied by the restoration of G protein-coupled receptor 43 (GPR43)/calcium/calmodulin-dependent protein kinase kinase 2 (CaMKK2)/AMPKα/sirtuin 1 (SIRT1) signaling and the activation of PI3K/AKT signaling, with decreased lipogenesis, enhanced fatty acid oxidation, reduced gluconeogenic gene expression, and alleviation of the cellular inflammatory response. In HFD-fed mice, NaB reduced body weight gain, improved serum and hepatic lipid profiles, attenuated hepatic steatosis, improved glucose tolerance and insulin sensitivity, and increased hepatic glycogen storage, while markedly lowering circulating and intrahepatic pro-inflammatory cytokine levels and downregulating hepatic expression of the macrophage marker F4/80 to mitigate inflammatory infiltration of the liver.
Conclusion
These results demonstrate that NaB administration alleviated hepatic steatosis and IR in MASLD models, with these effects coinciding with the coordinated regulation of AMPK and PI3K/AKT signaling. While NaB may serve as a metabolic modulator, further mechanistic validation of dual-pathway crosstalk, characterization of inflammatory responses, and translational research are still needed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Medical College of Qinghai University, 810000 Xining, Qinghai, China.
- Qinghai University Medical College, 810016 Xining, Qinghai, China.
- Department of Hepatology II, Fourth People's Hospital of Qinghai Province, 810000 Xining, Qinghai, China.
Zitieren
APA
Zhao, Y., Jiang, P., Zhang, Y., Wang, Y., Wang, Y., & Yu, G. (2026). Sodium Butyrate Ameliorates Hepatic Steatosis and Insulin Resistance in MASLD Models With Concurrent Alterations in AMPK and PI3K/AKT Signaling. Frontiers in Bioscience-Landmark, 31(10). https://doi.org/10.31083/fbl55577
Vancouver
Zhao Y, Jiang P, Zhang Y, Wang Y, Wang Y, Yu G. Sodium Butyrate Ameliorates Hepatic Steatosis and Insulin Resistance in MASLD Models With Concurrent Alterations in AMPK and PI3K/AKT Signaling. Frontiers in Bioscience-Landmark. 2026;31(10). doi:10.31083/fbl55577
BibTeX
@article{Zhao2026,
author = {Zhao, Yinan and Jiang, Ping and Zhang, Yiwen and Wang, Ya and Wang, Yige and Yu, Guoying},
title = {Sodium Butyrate Ameliorates Hepatic Steatosis and Insulin Resistance in MASLD Models With Concurrent Alterations in AMPK and PI3K/AKT Signaling},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
volume = {31},
number = {10},
doi = {10.31083/fbl55577}
}
EUVIMED